Journal of Cancer Research
- ISSN: 2578-3726
Alexandre Tavartkiladze, Gaiane Simonia, Ruite Lou, Pati Revazishvili, Dinara Kasradze, Maia Maisuradze, Nana Okrostvaridze and Levan Tavartkiladze
Cancer remains one of the leading causes of mortality worldwide, with traditional treatments often facing significant challenges
in terms of efficacy, resistance, and toxicity. As cancers progress to advanced stages, they frequently develop resistance to
monotherapies, underscoring the need for multi-targeted treatments that can address the complexity of tumor biology.
AminoSineTriComplex, a formulation of bioactive compounds derived from various medicinal plants, represents a promising
multi-targeted approach to oncological therapy. This study explores the effects of AminoSineTriComplex across several
carcinogen-induced rat models of breast, colon, and prostate cancers, with a focus on its mechanisms, pathway-specific actions,
and potential efficacy in diverse cancer types.
The composition of AminoSineTriComplex includes Epigallocatechin Gallate (EGCG), Resveratrol, Quercetin, Genistein,
Berberine, Sulforaphane, Apigenin, Luteolin, Honokiol, and Thymoquinone, each derived from well-known medicinal plants.
These compounds target a wide array of cancer-related pathways, including PI3K/AKT/mTOR, NF-κB, VEGF, Wnt/β-Catenin,
JAK/STAT, Hedgehog, Notch, and DNA damage repair mechanisms. This multi-pathway inhibition allows AminoSineTriComplex
to reduce cancer cell proliferation, induce apoptosis, limit angiogenesis, and suppress the invasive and metastatic potential of
tumors. Through these effects, AminoSineTriComplex offers a comprehensive approach to disrupting cancer growth at multiple
levels, a strategy that is particularly valuable in cancers prone to resistance.
In breast cancer models, AminoSineTriComplex demonstrated significant tumor stabilization, with some models achieving
partial or complete remission, particularly in hormone-sensitive and early-stage cases. Similarly, in prostate cancer models,
including both hormone-sensitive and androgen-insensitive types, AminoSineTriComplex showed high rates of remission and
stabilization, pointing to its potential as a standalone or adjunctive therapy in prostate cancer management. Colon cancer
models displayed a range of responses, with early-stage adenocarcinomas showing promising remission rates, while more
aggressive and resistant colon tumors presented challenges that indicate the need for combinatory therapies.
Potential applications of AminoSineTriComplex extend to brain cancers, particularly glioblastoma multiforme (GBM), where
PI3K/AKT, NF-κB, and VEGF pathways are central to tumor progression. Some components of AminoSineTriComplex, such as
EGCG and Resveratrol, have demonstrated a capacity to cross the blood-brain barrier, suggesting potential for application
in brain tumors, especially when paired with delivery systems designed to optimize bioavailability in the brain. Although
preclinical evidence on brain cancer efficacy is limited, the compound’s multi-pathway targeting aligns with the therapeutic
needs of aggressive brain cancers.
AminoSineTriComplex’s low toxicity profile, as observed in preclinical studies, enhances its suitability for integrative and longterm
use. Unlike conventional chemotherapies that often induce significant side effects, AminoSineTriComplex’s plant-based
bioactive compounds demonstrate a relatively high therapeutic index, allowing for sustained administration with minimal
adverse effects. This safety profile positions AminoSineTriComplex as a potential maintenance therapy to manage disease
progression in advanced cancer patients, as well as a candidate for combination with conventional therapies to potentially reduce the required doses and thus alleviate toxic side effects.
The findings of this study suggest that AminoSineTriComplex could serve as a valuable addition to oncological treatment
strategies, addressing multiple cancer types and stages through a holistic approach. Future clinical studies will be necessary to
validate these preclinical outcomes in human populations, optimize dosing strategies, and investigate the full therapeutic scope
of AminoSineTriComplex in various cancers. With its broad-spectrum targeting and low toxicity, AminoSineTriComplex could
redefine integrative cancer therapy, offering patients a safer and more comprehensive treatment option that aligns with the
growing demand for holistic and sustainable cancer care solutions.